Market research
TIVC Tivic Health Systems Inc
NASDAQ USD Healthcare
Latest close
As of 28 Jul 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.84
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 4M
- P/E ratio
- Not available
- Dividend yield
- Not available
- Beta
- 1.84
About
About Tivic Health Systems Inc
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Research context
Tivic Health Systems Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
0 comments
Sign in to join the TIVC discussion.
No comments yet
Start a focused discussion about TIVC.